JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2006; 47:529-537, doi:10.1016/j.jacc.2005.08.070 (Published online 13 January 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.08.070v1
47/3/529    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glaser, R.
Right arrow Articles by Kimmel, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glaser, R.
Right arrow Articles by Kimmel, S. E.

CLINICAL RESEARCH: PLATELET INHIBITION

The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes

A Cost-Effectiveness Analysis

Ruchira Glaser, MD*,*, Henry A. Glick, PhD{dagger}, Howard C. Herrmann, MD, FACC* and Stephen E. Kimmel, MD, MSCE, FACC*,{ddagger}

* Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
{dagger} University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
{ddagger} Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Manuscript received December 3, 2004; revised manuscript received July 22, 2005, accepted August 23, 2005.

* Reprint requests and correspondence: Dr. Ruchira Glaser, University of Pennsylvania School of Medicine, Medicine-Cardiology, 9 Founders Cardiology-HUP, 3400 Spruce Street, Philadelphia, Pennsylvania 19104. (Email: ruchira.glaser{at}uphs.upenn.edu).

OBJECTIVES: We endeavored to determine under what conditions a strategy of upstream use of small molecule platelet glycoprotein (GP) IIb/IIIa inhibitors for all acute coronary syndromes (ACS) patients is cost effective compared to that of selective use of abciximab in only those patients requiring percutaneous coronary intervention (PCI).

BACKGROUND: Small molecule GP IIb/IIIa inhibitors have shown benefit in ACS, but abciximab, the more expensive GP IIb/IIIa inhibitor, may be more effective during PCI. However, abciximab does not have proven efficacy in medical management. No prior study has attempted to balance these competing benefits.

METHODS: A decision analysis was performed to examine two strategies: 1) treat all ACS patients upstream with a small molecule GP IIb/IIIa inhibitor and continue through medical management and PCI, if performed; or 2) wait, and selectively use abciximab only in patients who ultimately undergo PCI. Applicable randomized controlled trial data were used for the principal analysis.

RESULTS: The strategy of upstream use of a small molecule GP IIb/IIIa inhibitor was superior to selective use, and economically acceptable, with a cost-effectiveness ratio of $18,000 per year of life gained. The superiority of the upstream use strategy persisted over the majority of sensitivity analyses. When stratified by risk according to Thrombolysis in Myocardial Infarction risk score, a strategy of upstream use was only cost effective in those patients with moderate or high risk.

CONCLUSIONS: Upstream use of small molecule GP IIb/IIIa inhibition in ACS patients with moderate or high risk for cardiovascular events is a cost-effective approach that should be considered in this subset of patients.

Abbreviations and Acronyms
  ACS = acute coronary syndromes
  CABG = coronary artery bypass graft
  GP = glycoprotein
  ICER = incremental cost-effectiveness ratio
  MI = myocardial infarction
  OR = odds ratio
  PCI = percutaneous coronary intervention
  QALY = quality-adjusted life years
  RR = relative risk
  TACTICS = Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy




This article has been cited by other articles:


Home page
Radiat Prot DosimetryHome page
R. H. Corbett
ETHICAL ISSUES, JUSTIFICATION, REFERRAL CRITERIA FOR BUDGET LIMITED AND HIGH-DOSE PROCEDURES
Radiat Prot Dosimetry, April 1, 2008; (2008) ncn089v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel
Reply
J. Am. Coll. Cardiol., January 16, 2007; 49(2): 277 - 277.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Boersma
Cost-Effectiveness of Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes
J. Am. Coll. Cardiol., January 16, 2007; 49(2): 276 - 276.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Kereiakes and E. M. Antman
Clinical Guidelines and Practice: In Search of the Truth
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1129 - 1135.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Upstream vs. Downstream GPIIb/IIIa Inhibition in ACS
Journal Watch Cardiology, March 16, 2006; 2006(316): 3 - 3.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.